News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aradigm Corporation (ARDM) And APT Pharmaceutical LLC Initiate Phase 2 Clinical Program Of Novel Treatment For Asthma


3/23/2006 12:07:42 PM

Aradigm Corporation (NASDAQ: ARDM) and APT Pharmaceuticals Inc., a privately held biotechnology company, today announced the initiation of their Phase 2 clinical trial investigating aerosolized hydroxychloroquine (HCQ) as an anti-inflammatory treatment for asthma. This clinical program will investigate the safety and efficacy of a novel aerosolized formulation of HCQ using Aradigm's AERx® pulmonary delivery system.

Read at BioSpace.com

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES